NCT03282396View on ClinicalTrials.gov

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

June 8, 2020

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

Ibrutinib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER